LivaNova

LivaNova is a global medical device and pharmaceutical company headquartered in London, UK, operating at the intersection of neuromodulation and cardiac surgery. The company is best known for its vagus nerve stimulation (VNS) therapy platform, which delivers targeted electrical impulses to the vagus nerve to modulate neurological activity in patients with drug-resistant conditions. Their flagship SenTiva device represents the most advanced iteration of this technology, offering personalized and automated therapy adjustments that respond dynamically to patient needs. This closed-loop approach to neuromodulation sets SenTiva apart from earlier generations of implantable neurostimulators, enabling more precise and individualized treatment outcomes.

LivaNova holds a well-established commercial position in the neuromodulation market, trading publicly on NASDAQ under the ticker LIVN, with a broad international commercial footprint spanning neurology and cardiac surgery. The company has accumulated decades of clinical evidence supporting VNS therapy for epilepsy, and has more recently advanced its pipeline into treatment-resistant depression, a historically underserved and difficult-to-treat patient population. Their long regulatory and reimbursement history in epilepsy has provided a durable foundation for market penetration, while ongoing clinical development continues to expand the therapeutic indications for their VNS platform. LivaNova has also pursued strategic acquisitions and partnerships to strengthen both its neuromodulation and cardiovascular portfolios over time.

LivaNova occupies a critical role in the broader neurotech industry as one of the few companies with a commercially approved, clinically validated implantable neuromodulation therapy at meaningful scale. Their work with VNS therapy has helped legitimize bioelectronic medicine as a viable treatment paradigm, demonstrating that modulating the nervous system through electrical stimulation can produce durable clinical benefits for complex neurological and psychiatric conditions. As the industry moves toward more adaptive and personalized neurostimulation, LivaNova's SenTiva platform serves as a meaningful benchmark for closed-loop device design. Their continued investment in expanding indications and refining stimulation protocols positions them as an important reference point for both clinical innovation and commercial execution in neuromodulation.